SCHEMBL23577271

SCHEMBL23577271

CN(c1cc(F)cc(Br)c1)c1nc2nncn2c2cc(C#N)ccc12

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
NCEH1 Q6PIU2 1/20 0.32
ABCG2 Q9UNQ0 1/20 0.31
CYP19A1 P11511 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29909658 1.00 NCEH1 (0.32) NCEH1ABCG2CYP19A1
SCHEMBL23576693 0.85 MAT2A (0.35)
SCHEMBL29909100 0.85 MAT2A (0.35)
SCHEMBL23576946 0.84
SCHEMBL23576663 0.83 KIF11 (0.30)
SCHEMBL29909628 0.83 KIF11 (0.30)
SCHEMBL23601193 0.82 ABCG2 (0.44) ABCG2
SCHEMBL30013722 0.82 CSNK2A1 (0.36) ABCG2
SCHEMBL23577324 0.81 MAPT (0.33) ABCG2
SCHEMBL29909815 0.81 MAPT (0.33) ABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-11-27 US disclosed
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-12-05 US disclosed
EP-4445902-A2 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2024-10-16 EP disclosed
EP-4081305-B1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES INC (JP) 2024-09-18 EP disclosed
US-12054490-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2024-08-06 US disclosed
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-06-06 US disclosed
CN-117736207-A Diacylglycerol kinase modulating compounds 卡尔那生物科学株式会社 2024-03-22 CN disclosed
CN-115362003-B Diacylglycerol kinase modulating compounds 卡尔那生物科学株式会社 2024-03-22 CN disclosed
US-11845723-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2023-12-19 US disclosed
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 US disclosed
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 US disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 WO disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK NCEH1 1129/4885ABCG2 4216/4885CYP19A1 3959/4885
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK NCEH1 1129/4885ABCG2 4216/4885CYP19A1 3959/4885
US-12054490-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK NCEH1 1129/4885ABCG2 4216/4885CYP19A1 3959/4885
US-11845723-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK NCEH1 1129/4885ABCG2 4216/4885CYP19A1 3959/4885
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK NCEH1 1129/4885ABCG2 4216/4885CYP19A1 3959/4885
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK NCEH1 1129/4885ABCG2 4216/4885CYP19A1 3959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.